Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 164

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 164
---
 unknown liabilities; |

| • |     | higher than expected acquisition or integration costs; |

| • |     | incurrence of substantial debt or dilutive issuances of equity securities to fund future operations; |

| • |     | write-downs of assets or incurrence of non-recurring, impairment or other 
 charges;                                                                  |

| • |     | increased amortization expenses; |

| • |     | difficulty and cost in combining the operations and personnel of any acquired business with its operations and 
 personnel;                                                                                                     |

| • |     | impairment of relationships with key suppliers or customers of any acquired business due to changes in management 
 and ownership; and                                                                                                |

| • |     | possibility of future litigation. |

99

Any of the foregoing risks could have a material adverse effect on Kineta’s business,
financial condition and prospects.

Kineta may not fully realize the expected cost savings and/or operating efficiencies from its restructuring activities and its ability to consummate a strategic transaction depends on its ability to retain its employees required to consummate such transaction.

On February 29, 2024, Kineta announced that it had completed a review of its business, including the status of its programs, resources and
capabilities. Following this review, Kineta implemented a significant corporate restructuring to substantially reduce expenses and preserve cash. The restructuring included a reduction in its workforce by approximately 64% and the termination of
enrollment of new patients in its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. Patients currently enrolled in the trial were permitted to continue to
participate. The Company made this decision, in part, because certain investors failed to fulfill their contractual obligation to fund and the second closing of the private placement for an aggregate purchase price of $22.5 million did not occur.

The Company believes these changes were needed to streamline its organization and reallocate its resources to better align with its
current strategic goals, including its current focus on pursuing strategic alternatives. However, these expense reduction measures have and may continue to yield unintended consequences and costs, such as the loss of institutional knowledge and
expertise, attrition beyond the Company’s intended reductions in workforce, a reduction in morale among its remaining employees, and the risk that the Company may not achieve the anticipated benefits, all of which may have an adverse effect on
the Company’s results of operations or financial condition.

Kineta’s ability to consummate a strategic transaction depends upon
its ability to retain its employees required to